Sindhu T. J.

Sindhu T. J.

Auto-generated profile, based on publicly available information

Sindhu T. J.

Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Deralakatte, Mangaluru 575018, Karnataka, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 September 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZCZAKIYA FATHIMA C
ZAKIYA FATHIMA C
JJJAINEY P JAMES
JAINEY P JAMES
MSMahendra Gowdru Srinivasa
Mahendra Gowdru Srinivasa
SJSindhu T. J
Sindhu T. J
MMMariyam Jouhara B. M.
Mariyam Jouhara B. M.
SGSudeep D. Ghate
Sudeep D. Ghate
Objective: Mucuna pruriens (Velvet beans) is a leguminous plant recognised in Vedic therapy as an anti-Parkinsonism agent. The plant is known as the natural reservoir for levodopa. The study aims to evaluate the multitarget inhibitory potency of active constituents present in Mucuna pruriens using in silico tools. Methods: The phytoconstituents present in Mucuna pruriens were retrieved from the IMPPAT database. The physicochemical and toxicity parameters of phytoconstituents were evaluated using Qikprop and ProTox-3. The inhibitory potential of phytoconstituents on the enzymes Monoamine Oxidase-B (MAO-B), Acetylcholinesterase (AChE), and Catechol-O-Methyltransferase (COMT) was evaluated using in silico techniques, including molecular docking, pharmacophore modelling, and molecular dynamics simulations, conducted with Schrödinger software programs. Results: The active constituents comply with Lipinski’s rule for drug-likeness. Further, the molecular docking studies revealed the phytoconstituent luteolin and acacetin showed promising multitargeted inhibitory properties. Especially luteolin (-11.504 kcal/mol) and acacetin (-10.620 kcal/mol) have obtained excellent docking scores with MAO-B, whereas the known drug levodopa showed a docking score of-8.501 kcal/mol. The pharmacophore modelling revealed that donor, acceptor, and aromatic features present in luteolin and acacetin are the essential pharmacophoric features accountable for biological activity. The simulation study generated the stability of the protein-ligand complex and found that luteolin showed a stable complex with MAO-B. Conclusion: Based on these findings, the result of the current study can be used to develop a novel luteolin-based drug for treating Parkinson’s disease with preferred structural modification. However, additional and more comprehensive research is required on this compound.

14 December 2024 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
ZCZAKIYA FATHIMA C
ZAKIYA FATHIMA C
JJJAINEY P JAMES
JAINEY P JAMES
PDPrarambh S R Dwivedi
Prarambh S R Dwivedi
TST. J. Sindhu
T. J. Sindhu

7 November 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
SJSindhu T. J.
Sindhu T. J.
JJJAINEY P JAMES
JAINEY P JAMES
ZCZAKIYA FATHIMA C
ZAKIYA FATHIMA C
RVRajalakshimi Vasudevan
Rajalakshimi Vasudevan
SAShankar G Alegaon
Shankar G Alegaon
Objective: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder involving oxidative stress, protein aggregation, and neurotransmitter imbalance. This study aimed to evaluate the neuroprotective potential of Drynaria quercifolia (DQ) phytoconstituents, particularly DQ5 (naringin), using in silico, in vitro, and pharmacological analyses for multitargeted AD therapy. Methods: Phytocompounds from DQ were analysed through molecular docking to assess binding affinities with AD-related targets, including acetylcholinesterase (AChE), monoamine oxidase-B (MAO-B), and peroxiredoxin-5 (Prdx-5). DQ5 (naringin) was further evaluated using molecular dynamics (MD) simulations and pharmacophore modelling. Density Functional Theory (DFT) was employed to assess molecular stability and reactivity. In vitro assays measured AChE, MAO-B, tyrosinase inhibition, and hydrogen peroxide scavenging. Neuroprotective effects were evaluated using MTT assay on SH-SY5Y neuroblastoma cells. Results: Molecular docking showed strong binding of DQ5 to AChE (-14.182 kcal/mol) and MAO-B (-13.393 kcal/mol). MD simulations confirmed complex stability. DQ5 (naringin) exhibits high stability in its gas-phase optimised structure, and its small HOMO-LUMO gap indicates it may be quite reactive, which could contribute to its biological activity. DQ5 inhibited AChE (IC₅₀ = 8.05±1.02 µg/ml) and 90% SH-SY5Y cell viability. Pharmacokinetic predictions supported favourable drug-likeness and safety profiles. Conclusion: DQ5 (naringin), a key metabolite from DQ, exhibits significant multitarget activity against AD-related enzymes and oxidative stress. The compound's pharmacological properties and neuroprotective effects highlight its promise as a natural therapeutic candidate for addressing multiple pathways involved in AD pathogenesis.

1 January 2026 in Journal of Chemistry
Verified
Journal Article
Open access
ZCZAKIYA FATHIMA C
ZAKIYA FATHIMA C
JJJAINEY P JAMES
JAINEY P JAMES
SGSrinivas Ganjipete
Srinivas Ganjipete
Parasuraman PavadaiParasuraman Pavadai
Parasuraman Pavadai
SJSindhu T. J.
Sindhu T. J.
Background: Monoamine oxidase‐B (MAO‐B) is a pivotal enzyme in the pathophysiology of Parkinson’s disease (PD), where its elevated activity accelerates dopamine catabolism, increases oxidative stress and contributes to the progressive loss of dopaminergic neurons. This study investigates the MAO‐B inhibitory potential of a series of pyrazole‐based chalcone derivatives using an integrated computational framework. Methods: A ligand library was generated through R‐group enumeration and screened for physicochemical suitability and pharmacokinetic compliance. Molecular docking against MAO‐B (PDB ID: 2BYB) was performed to evaluate binding affinity, which was further validated through MM‐GBSA binding free‐energy calculations. Pharmacophore modelling using Phase identified the key structural features governing MAO‐B inhibition. The top‐ranked complexes were subjected to molecular dynamics simulations to assess structural stability. Density functional theory (DFT) calculations were conducted to examine electronic reactivity, including HOMO–LUMO gaps and related quantum descriptors. Results: The designed ligands demonstrated favourable physicochemical and pharmacokinetic profiles. Docking studies indicated strong binding affinities, with several compounds outperforming the reference inhibitor deprenyl, consistent with MM‐GBSA predictions. Pharmacophore modelling revealed a five‐point AHHRR_1 hypothesis as the critical determinant of activity. Hydrophobic 3,5‐dimethyl substitutions on the pyrazole ring enhanced electron density and inhibitory potency, while the conjugated π‐system between pyrazole and phenyl moieties contributed to stabilised π–π interactions. Para‐substituted electron‐withdrawing groups on the phenyl ring further improved MAO‐B selectivity. Molecular dynamics simulations confirmed robust complex stability, with the 5b/2BYB complex exhibiting low RMSD, minimal residue fluctuations and persistent hydrogen‐bonding and hydrophobic contacts. DFT analysis revealed narrow HOMO–LUMO gaps, indicative of high electronic reactivity and strong binding propensity. Conclusion: Overall, this comprehensive computational investigation offers valuable insights for the rational design and optimisation of pyrazole–chalcone derivatives as promising MAO‐B inhibitors for PD therapy and supports their further in vitro and in vivo evaluation.